Sponsorship Statement:
This continuing education activity is jointly-sponsored by
and
Support Statement:
This activity is supported by an educational grant from
Target Audience: The intended audience for the activities is oncologists, hematologists/oncologists, oncology nurses, and other healthcare professionals involved in the treatment of patients with cancer.
Learning Objectives: Upon completion of this activity, participants should be able to:
- Describe the mechanism of action of integrin inhibitors in the treatment of gliomas and glioblastomas.
- Evaluate preclinical and clinical data on the efficacy and safety of integrin inhibitors.
- Identify and enroll appropriate patients in suitable ongoing clinical trials that evaluate integrin inhibitors, alone and in combination with other therapies, for the treatment of gliomas and glioblastomas.
Course Chair:
Marc C. Chamberlain, MD
University of Washington
Department of Neurology and Neurological Surgery
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington
Faculty:
David A. Reardon, MD
Associate Professor, Department of Surgery
Associate Professor, Department of Pediatrics
Associate Deputy Director, The Preston Robert Tisch Brain Tumor Center at Duke
Duke University Medical Center
Durham, NC
Patrick Y. Wen, MD
Director, Neuro-Oncology
Professor of Neurology, Harvard Medical School
Dana Farber Cancer Institute
Boston, MA
External Reviewer:
Mark R. Gilbert, MD
Accreditation:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of HEMONC TODAY® and Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This continuing nursing education activity is provided by Vindico Medical Education.
Vindico Medical Education is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. P#188-6/2009-2012.
Nurse practitioners can apply for
AMA PRA Category 1 Credit(s)TM through the American Academy of Nurse Practitioners (AANP). AANP will accept
AMA PRA Category 1 Credit(s)TM from organizations accredited by Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Credit Designation:
Vindico Medical Education designates this educational activity for a maximum of 0.75
AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide 0.75 contact hours for nurses.
This enduring material is approved for 1 year from the date of original release, July 22, 2011 to July 21, 2012.
How To Participate in this Activity and Obtain CME/CNE Credit:
To participate in this CME/CNE activity, you must read the objectives, answer the Pretest questions, watch and listen to the presentations, complete the Posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the Posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the Posttest is achieved, Vindico Medical Education will issue an
AMA PRA Category 1 Credit(s)TM certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the
relevant financial relationships of the planners, teachers, and authors involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control. Relationship information appears on this page and the next page.The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Marc C. Chamberlain, MD
Consulting Fees:Genentech, Roche, Exelixis
Fees for NON-CME services received directly from Commerical Interest or their Agents: Genentech, Roche, Exelixis
David A. Reardon, MD
Fees: EMD Serono, Merck, Schering, Genentech, Roche
Patrick Y. Wen, MD
Consulting Fees: Ark Therapeutics, Agios, Genzyme, Novartis, Imclone/Lilly
Contract Research: Boehringer Ingelheim, Amgen, Astra Zeneca, Esai, Exelixis, Genentech, Merck, Novartis
External Reviewer reports the following relationship(s):
Mark R. Gilbert, MD
Consulting Fees: Abbott, Merck, Genentech, Tau
HEMONC TODAY® and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2011 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of HEMONC TODAY® and Vindico Medical Education, continuing medical education activities does not necessarily reflect the views and opinions of HEMONC TODAY® or Vindico Medical Education. Neither HEMONC TODAY®, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.